PMC:7546122 / 512-787 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7546122","sourcedb":"PMC","sourceid":"7546122","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7546122","text":"ends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly po","tracks":[{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":23,"end":37},"obj":"Body_part"},{"id":"T4","span":{"begin":163,"end":177},"obj":"Body_part"},{"id":"T5","span":{"begin":206,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62970"},{"subj":"T3","pred":"source","obj":"LitCovid-PD-FMA-UBERON"},{"subj":"T4","pred":"source","obj":"LitCovid-PD-FMA-UBERON"},{"subj":"T5","pred":"source","obj":"LitCovid-PD-FMA-UBERON"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":140,"end":147},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T6","span":{"begin":206,"end":212},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"attributes":[{"subj":"T5","pred":"source","obj":"LitCovid-PD-CLO"},{"subj":"T6","pred":"source","obj":"LitCovid-PD-CLO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PD-FMA-UBERON","color":"#93a4ec","default":true},{"id":"LitCovid-PD-CLO","color":"#beec93"}]}]}}